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Abstract
Avian mycoplasmosis (Mycoplasma gallisepticum, Mycoplasma meleagridis) has been assessed
according to the criteria of the Animal Health Law (AHL), in particular criteria of Article 7 on disease
proﬁle and impacts, Article 5 on the eligibility of avian mycoplasmosis to be listed, Article 9 for the
categorisation of avian mycoplasmosis according to disease prevention and control rules as in Annex
IV and Article 8 on the list of animal species related to avian mycoplasmosis. The assessment has been
performed following a methodology composed of information collection and compilation, expert
judgement on each criterion at individual and, if no consensus was reached before, also at collective
level. The output is composed of the categorical answer, and for the questions where no consensus
was reached, the different supporting views are reported. Details on the methodology used for this
assessment are explained in a separate opinion. According to the assessment performed, avian
mycoplasmosis can be considered eligible to be listed for Union intervention as laid down in Article 5
(3) of the AHL. The disease would comply with the criteria as in Sections 4 and 5 of Annex IV of the
AHL, for the application of the disease prevention and control rules referred to in points (d) and (e) of
Article 9(1). The assessment here performed on compliance with the criteria as in Section 3 of Annex IV
referred to in point (c) of Article 9(1) is inconclusive. The animal species to be listed for avian
mycoplasmosis according to Article 8(3) criteria are mainly domestic and wild birds of the order
Galliformes, and also Passeriformes for M. gallisepticum.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017).
The present document reports the results of assessment on avian mycoplasmosis
(Mycoplasma gallisepticum, Mycoplasma meleagridis) according to the criteria of the AHL articles as
follows:
• Article 7: avian mycoplasmosis (M. gallisepticum, M. meleagridis) proﬁle and impacts
• Article 5: eligibility of avian mycoplasmosis (M. gallisepticum, M. meleagridis) to be listed
• Article 9: categorisation of avian mycoplasmosis (M. gallisepticum, M. meleagridis) according to
disease prevention and control rules as in Annex IV
• Article 8: list of animal species related to avian mycoplasmosis (M. gallisepticum,
M. meleagridis).
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of avian mycoplasmosis (M. gallisepticum, M. meleagridis)
according to the Article 7 criteria of the AHL and related parameters (see Table 2 of the opinion on
methodology (EFSA AHAW Panel, 2017)), based on the information contained in the fact-sheet as
drafted by the selected disease scientist (see Section 2.1 of the scientiﬁc opinion on the ad hoc
methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
M. gallisepticum
Naturally M. gallisepticum infections occur in several wild avian species. In Europe, the main wild
avian species affected by M. gallisepticum infections are game birds (belonging to the order
Galliformes): pheasants, grey partridges, chukar partridges, etc.; often because of captive rearing
conditions resembling those of domestic Galliformes such as chickens and turkeys (Nicholas, 2012).
But other bird orders can also be affected: a recent Belgian study detected M. gallisepticum in one
wood pigeon (Columbiformes), two grey herons (Pelecaniformes), one mallard (Anseriformes) and one
Eurasian magpie (Passeriformes) (Michiels et al., 2016). In the USA, M. gallisepticum was detected in
birds belonging to the order Galliformes (wild turkeys, peafowls, peacocks, bobwhite quail) and
Passeriformes (house ﬁnches, rooks, American goldﬁnches, pine grosbeaks, evening grosbeaks, purple
ﬁnch and blue jay) (for review, see Stipkovits and Kempf, 1996; Raviv and Ley, 2013). Cases were
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reported for Japanese quails (Passeriformes) and parrots (Psittaciformes). Antibodies were also
detected in several other bird species (Luttrell et al., 2001; Dhondt et al., 2014).
M. meleagridis
M. meleagridis is a speciﬁc pathogen of turkeys (order Galliformes) (for review see Chin, 2013) and
wild turkeys in America are therefore susceptible to this disease (Charlton, 2000). No other data are
available about another susceptible wildlife species (clinical signs or lesions). However, seropositivity is
often reported in several wild bird species: antibodies were found in sera of other bird species belonging
to the order Galliformes (lesser prairie chickens and peafowls in the USA (Hagen et al., 2002; Hollamby
et al., 2003) and of a scaled quail in Mexico (Aguirre et al., 1992)). Occurrence of M. meleagridis in
peacocks and Japanese quail (Galliformes), and pigeons (Columbiformes) was also reported (Yamamoto,
1991). M. meleagridis was also isolated from birds of prey (Falconiformes) without clinical signs or
histopathological alterations in air sac biopsies in Germany (Aguirre et al., 1992; Lierz et al., 2000).
Parameter 2 – Naturally susceptible domestic species (or family/orders)
M. gallisepticum
M. gallisepticum infections occur mostly in domestic Galliformes, mainly chickens and turkeys
(Stipkovits and Kempf, 1996; Raviv and Ley, 2013), but has also been described in geese and ducks
(Jordan and Amin, 1980; Buntz et al., 1986; Bencina et al., 1987, 1988).
M. meleagridis
M. meleagridis was thought to be very host-speciﬁc and only restricted to turkeys but
M. meleagridis was recently isolated from chicken breeders with respiratory symptoms and poor
performances reared near a turkeys breeding unit in Tunisia (Bejaoui Khiari et al., 2011).
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
M. gallisepticum
Experimental infections were carried out on several wild species of birds. House sparrows and
pigeons are none to mildly susceptible (Dhondt et al., 2008; Gharaibeh and Hailat, 2011), whereas
house ﬁnches are very susceptible (Sydenstricker et al., 2006; Dhondt et al., 2008). American
goldﬁnches develop intermediate clinical signs (Dhondt et al., 2008). Chukar partridges were also used
as experimental models with development of clinical signs and lesions (McMartin et al., 1996).
M. meleagridis
No reports available on experimentally infected wildlife species for M. meleagridis.
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
M. gallisepticum
Most of experimental studies were performed on chickens and turkeys (for review see Stipkovits
and Kempf, 1996; Raviv and Ley, 2013) which are susceptible for the infection. However, studies were
also carried out on budgerigars and canaries with development of clinical signs and lesions (Brown and
Butcher, 1991; Hawley et al., 2011).
M. meleagridis
Experimental infections were conducted on turkeys and turkey embryos, leading to airsacculitis,
deciliation of trachea, induced curved toes, ﬁssures of the cartilage, alterations of the eggshell
membranes (Lam et al., 2003a,b, 2004).
One experiment performed on chicken embryos resulted in abnormal-shaped toes and severely
denuded tracheae (Lam, 2004).
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
M. gallisepticum
As described below in Section 3.1.1.6 Parameter 1, airborne transmission is a major way of
transmission of M. gallisepticum between birds. Wild birds described in Section 3.1.1.1 can therefore
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be reservoir animals (Ferguson et al., 2003) as M. gallisepticum infections do not always lead to clinical
signs. However, wild birds probably play a limited role as a reservoir compared to domestic species
such as chickens and turkeys.
M. meleagridis
As described below in Section 3.1.1.6 Parameter 1, airborne transmission is apparently of little
signiﬁcance for M. meleagridis transmission compared to vertical transmission (Stipkovits and Kempf,
1996; Chin, 2013). Therefore, even if this Mycoplasma species can be isolated or detected by serology
in some other avian species described below, it is quite unlikely that these species may act as a
reservoir for M. meleagridis infection in turkeys.
As described in Section 3.1.1.6 Parameter 1, M. meleagridis was isolated from birds of prey in
Germany (Aguirre et al., 1992; Lierz et al., 2000) and antibodies were also found in sera of lesser
prairie chickens, peafowls, a scaled quail, peacocks, pigeons and Japanese quails (Yamamoto, 1991;
Hagen et al., 2002). However, no reports showed evidence of turkey ﬂock recontamination from these
bird species.
Parameter 6 – Domestic reservoir species (or family/orders)
M. gallisepticum
Backyard ﬂocks and multiage ﬂocks (especially laying-hen ﬂocks) can be reservoir for
M. gallisepticum infections (Mohammed et al., 1987; McBride et al., 1991; Haesendonck et al., 2014).
M. meleagridis
M. meleagridis was isolated from chicken and turkey ﬂocks near turkey breeding units or meat
turkey ﬂocks (McBride et al., 1991; Bejaoui Khiari et al., 2011).
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/incidence
M. gallisepticum
M. gallisepticum infections have a worldwide distribution. They resulted in important ﬂock health
problems before implementation of control programmes, which succeeded in reducing the prevalence
of M. gallisepticum in all areas of commercial productions, especially in the USA and Europe (Levisohn
and Kleven, 2000). However, outbreaks of M. gallisepticum infections continue to occur in production
ﬂocks and M. gallisepticum is endemic in many multiage commercial egg production farms (Levisohn
and Kleven, 2000; Raviv and Ley, 2013). Recent studies on prevalence of M. gallisepticum in Europe
are scarce. A seroprevalence of 2.4% was found in Latvia (Zute and Valdovska, 2015). Two studies
performed in France in 1998 and in 2003 showed a low seroprevalence of M. gallisepticum (between
0% and 2%) in laying hen ﬂocks (Kermorgant, 1999; Dufour-Gesbert et al., 2006). Likewise, in
Germany, Kohn et al. (2009) did not detect M. gallisepticum infection in laying hens from different
housing systems. However, antibodies against M. gallisepticum were found in 36.7% of birds from
backyard and fancy poultry ﬂocks in Belgium (Haesendonck et al., 2014), highlighting the possible risk
of transmission to commercial ﬂocks.
Seroprevalence of M. gallisepticum in other countries outside Europe is often much higher: 69.9%
in broiler and laying chickens in Algeria (Heleili et al., 2012) and 56.1–64.5% in Bangladesh (Ali et al.,
2015). M. gallisepticum was also detected by polymerase chain reaction (PCR) in 18.7% of samples
from breeder, broiler and layer ﬂocks (Faisal et al., 2011).
M. meleagridis
Studies performed before 1980 showed that M. meleagridis was a common pathogen of turkeys with
a worldwide distribution (Vlaovic and Bigland, 1971; Rosenfeld and Grimes, 1972; Shimizu and Yagihashi,
1980). However, little recent data is available on prevalence/incidence of this disease as intensive
eradication programmes were conducted to eliminate M. meleagridis from turkey breeder ﬂocks (Chin,
2013). These programmes succeeded in reducing the prevalence of M. meleagridis infections in
the major producing areas of the world. Studies performed in Germany and Belgium on several
turkey ﬂocks showed that M. meleagridis infections could not be detected (Van Loock et al., 2005).
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More recently, M. meleagridis was detected by PCR in 3/624 (0.5%) meat-type turkeys randomly
selected in Turkey (Ongor et al., 2009).
Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
M. gallisepticum
M. gallisepticum causes chronic respiratory disease in chickens and infectious sinusitis in turkeys
characterised by rales, coughing, nasal discharge, sinusitis and the development of severe airsacculitis
(Stipkovits and Kempf, 1996; Raviv and Ley, 2013). M. gallisepticum infections usually affect nearly all
chickens in a ﬂock but severity and duration of disease are variable. It affects males and young birds
more severely than females and adult birds. The disease is also more severe in winter than in summer.
In broilers, M. gallisepticum infections lead to retarded growth with a reduction in weight gain up to
20–30% and to a 10–20% decrease in food conversion efﬁciency. Clinical signs and lesions are also
source of 10–20% of condemnations or downgrading of carcasses in slaughterhouses (Stipkovits and
Kempf, 1996).
In breeders and laying hens, M. gallisepticum infection is responsible for a 10–20% decrease in egg
production.
Escherichia coli and Infectious Bronchitis virus (IBV) infections lead to complicated diseases with
more severe clinical signs and lesions and a higher morbidity rate. Moreover, vaccination programmes
against infectious bursal disease (IBD), IBV, laryngotracheitis and infectious coryza signiﬁcantly
increase economic losses due to M. gallisepticum infection (Stipkovits and Kempf, 1996; Raviv and Ley,
2013).
Turkeys are more susceptible to M. gallisepticum infections than chickens, developing more severe
clinical signs such as marked swelling of infraorbital sinuses: partial to complete closure of the eyes
can affect 1–70% of birds in affected ﬂocks and can lead to weight losses when birds cannot see to
eat (Raviv and Ley, 2013). However, clinical signs may be highly variable within a ﬂock or between
ﬂocks.
M. meleagridis
M. meleagridis causes late incubation mortality (from 25 to 28 days of incubation) in infected
turkey embryos (Carpenter et al., 1981), with a loss of hatchability of 5–6% of fertile eggs, but does
not affect egg production or fertility in adult birds (Chin, 2013).
Most of problems are seen in young birds: 10–25% of young turkeys under 15–16 weeks can show
M. meleagridis-associated air sacculitis; 5–10% may show M. meleagridis-associated skeletal
abnormalities such as wry necks, twisting and shortening of the tarso-metatarsal bones (Wise et al.,
1973; Chin, 2013). Reduction of growth rate is not always observed in M. meleagridis-infected ﬂocks
compared to M. meleagridis-free ﬂocks (Wise et al., 1973; Carpenter et al., 1982).
Mortality
Parameter 3 – Case-fatality rate
M. gallisepticum
Experimental inoculation of M. gallisepticum in embryos usually results in embryo deaths within
5–7 days. Natural infection leads to a 5–10% increase in embryo mortality (Stipkovits and Kempf,
1996; Raviv and Ley, 2013). In broilers, the mortality may range from low in uncomplicated disease to
as much as 30% in severe outbreaks due to concurrent infections (E. coli or viruses) and
environmental factors (ammoniac, low or high temperatures).
Mycoplasma, and especially M. gallisepticum infections are source of morbidity (sinusitis and
conjunctivitis) and mortality rates of 5–10% in game birds housed in high density (Nicholas, 2012).
According to several studies, M. gallisepticum was responsible for up to 60% of population decline in
house ﬁnches in the USA (Luttrell et al., 2001; Sydenstricker et al., 2006; Raviv and Ley, 2013).
M. meleagridis
Except embryo mortality, M. meleagridis infections do not lead to direct mortality, which is due
primarily to cannibalism of affected birds (Chin, 2013).
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3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
M. gallisepticum
No reports of zoonotic human cases have been published. M. gallisepticum infects a relatively
narrow range of exclusively avian host species and has no public health signiﬁcance.
M. meleagridis
No reports of zoonotic human cases have been published. M. meleagridis infects a very narrow
range of exclusively avian host species as listed in Section 3.1.1.1.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
M. gallisepticum
Because M. gallisepticum is a wall-less bacteria, it is assumed that most of the commonly employed
chemical disinfectants are effective against this Mycoplasma species (Brunner and Laber, 1985; Raviv
and Ley, 2013).
M. gallisepticum, as other Mycoplasma species, is naturally resistant to penicillin and other
antibiotics acting on cell-wall synthesis. Several studies showed that most of ﬁeld strains are
susceptible in vitro and in vivo to several antibiotics of the tetracycline, macrolide, pleuromutilin and
ﬂuoroquinolone families (for review see Brunner and Laber, 1985; Raviv and Ley, 2013). However,
recent studies showed that M. gallisepticum can develop resistance and cross-resistance mechanisms
to several antimicrobials (within an antimicrobial family) (Raviv and Ley, 2013; Ammar et al., 2016).
However, no strain was found to be resistant to all treatments in vivo or in vitro.
M. meleagridis
There are a very low number of publications on M. meleagridis and resistance to treatments. It is
assumed that most chemical disinfectants would be effective on Mycoplasma species as these bacteria
do not have a cell wall (Brunner and Laber, 1985).
As occurrence of M. meleagridis infections is very low, due to eradication programmes, no recent
studies were performed on minimum inhibitory concentration (MIC) determination. Most studies on
efﬁcacy of different antibiotics (gentamycin, tetracyclines, macrolides, spectinomycin, ﬂuoroquinolones)
against M. meleagridis-induced clinical signs were carried out in vivo or in ovo before or at the
beginning of eradication programs between 1970 and 1982 (for review see Brunner and Laber, 1985;
Chin, 2013). A publication on antibiotic MIC determination against M. meleagridis in 1989 showed that
the four strains tested were susceptible to enroﬂoxacin, tylosin and tiamulin (Jordan et al., 1989).
However, M. meleagridis strains resistant to tylosin have been reported in 1969 (Chin, 2013).
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
M. gallisepticum
Transmission may be more likely during the acute phase of infection (usually 4–8 weeks after
infection) when a large quantity of Mycoplasma may be excreted by nasal discharge, breathing or
coughing. However, once a bird is infected by M. gallisepticum, it is considered chronically infected for
life and it is a source of infection for other birds. Thus, infected ﬂocks are often sources of new
infections (in the same farm or in neighbouring farms).
M. meleagridis
Several old studies showed that once established, M. meleagridis reproductive tract infections in
turkey hens and males persist for long periods (Kumar and Pomeroy, 1969; Rhoades, 1969, 1971;
Chin, 2013), with variation during the laying period (Kumar and Pomeroy, 1969; Rott et al., 1989).
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These genital infections are the main way of transmission: once contaminated, a turkey (male or
female) remains a source of contamination (infected eggs and poults for the hens, contaminated
semen for the males). Tracheal infections are observed only in the ﬁrst 14 weeks of age (Stipkovits
and Kempf, 1996; Chin, 2013).
Parameter 2 – Presence and duration of latent infection period
M. gallisepticum
M. gallisepticum incubation period varies from 6 to 21 days, but development of clinical signs can
be highly variable depending on strain virulence, concomitant infections (other bacteria or viruses) and
other stresses (Raviv and Ley, 2013).
M. meleagridis
Isolation of M. meleagridis and development of air-sac lesions are observed after an incubation period
of 1–2 weeks after infection in poults (Rhoades, 1971). M. meleagridis can be isolated from respiratory
and reproductive tracts of experimentally infected adult turkeys from 2 weeks after exposure.
Parameter 3 – Presence and duration of the pathogen in healthy carriers
M. gallisepticum
In general, Mycoplasma infections, once established, are known to persist for all of the ﬂock’s life:
persistence of M. gallisepticum in infected chickens and turkey has been described (Stipkovits and
Kempf, 1996; Reinhardt et al., 2005; Raviv and Ley, 2013). Chickens and turkeys often develop clinical
signs near the onset of egg production, or after a vaccination (or another operation on animals),
suggesting a low level of subclinical infection without antibody response (healthy carrier state) that
becomes clinical in response to a stress. At later stages of infection, the number of M. gallisepticum
organisms in chronically infected birds, such as commercial layers or backyard poultry, may be so low
that M. gallisepticum may not be detected by usual sampling and culture methods (Raviv and Ley,
2013). However these birds still remain a possible source of infection since additional stresses (bad
environmental conditions, vaccinations, etc.) or infection with other microorganisms can increase
excretion of M. gallisepticum in these birds (Stipkovits and Kempf, 1996).
M. meleagridis
In general, Mycoplasma infections, once established, are known to persist for all the ﬂock’s life. As
described in Section 3.1.1.5 Parameter 1, persistence of M. meleagridis in the genitalia of adult turkeys
has been reported for several weeks without clinical signs and lesions (Kumar and Pomeroy, 1969;
Rhoades, 1969, 1971; Chin, 2013). Cloacal infection detected in the male at the time of hatch can
persist through sexual maturity. Infection may occur without clinical signs and lesions in adult birds.
Moreover, adult males can be serologically negative carriers of M. meleagridis (Rhoades, 1971).
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
M. gallisepticum
Several studies were performed on M. gallisepticum survival in the environment (for review see
(Stipkovits and Kempf, 1996; Raviv and Ley, 2013)). The survival time of M. gallisepticum outside of a
host varies from 1 to 14 days and depends upon environmental conditions (mainly substrate (faeces,
feathers, dust, clothes and human hair, etc.) on which M. gallisepticum cells are found, but also
temperature, humidity and pH). The longest survival time was found in egg material: up to 3 weeks in
allantoic ﬂuid, and up to 18 weeks in egg yolk. PCR is more sensitive than culture for assessing
dissemination of M. gallisepticum in poultry environment, but it detects viable and non-viable bacteria
(Marois et al., 2002a).
M. meleagridis
Very few studies were performed on M. meleagridis survival in the environment as the major way
of transmission is the vertical one. M. meleagridis was recovered from an artiﬁcially created aerosol in
gradually decreasing amounts during a 6-h period (Beard and Anderson, 1967). M. meleagridis is able
to survive in turkey semen during cryopreservation and subsequent thawing (Ferrier et al., 1982).
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Studies on other avian Mycoplasma species have shown that these bacteria are able to survive on
different matrices from several hours to several days (Christensen et al., 1994; Marois et al., 2002b).
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
M. gallisepticum
The main route for the spread of M. gallisepticum infection is vertical transmission through eggs
(Stipkovits and Kempf, 1996; Raviv and Ley, 2013). Even if a proportion of infected embryos die during
incubation (5–10% increase in embryo mortality), other embryos will hatch, carrying the infection to
the progeny ﬂock. Consequently, infection can be carried on long distances by M. gallisepticum-
infected eggs or 1-day-old chicks.
Horizontal transmission occurs readily by direct or indirect contact of susceptible birds with infected
birds (clinical or subclinical carriers) (Stipkovits and Kempf, 1996; Raviv and Ley, 2013): a large
quantity of mycoplasma can be excreted by nasal discharge, breathing or coughing during the acute
phase of infection. Transmission of infection may also occur through artiﬁcial insemination since
M. gallisepticum can be found in semen. Additional transmission and more widespread disease
outbreaks may occur via fomites (M. gallisepticum found on dust, feathers, etc.) and suboptimal
biosecurity measures and personnel practices (M. gallisepticum found on human hair and clothes, in
the nasal passage). Egg debris in incubators is also essential in spreading infection (Stipkovits and
Kempf, 1996).
M. meleagridis
Direct horizontal transmission of M. meleagridis can occur by the airborne route within the hatchery
and ﬂock and between ﬂocks separated by 400 meters (Kumar and Pomeroy, 1969; Stipkovits and
Kempf, 1996; Chin, 2013). Airborne transmission in mature turkey results in infections localised in the
sinus and trachea, whereas airborne infections of young birds can lead to genitalia localisation.
Indirect transmission can occur at any time of the bird’s life during interventions (sexing, palpation
of hens, vaccination) with contaminated hands, clothing and equipment. Adult females can also be
infected by insemination with M. meleagridis-contaminated semen from infected males (Kumar and
Pomeroy, 1969; Stipkovits and Kempf, 1996; Chin, 2013).
The horizontal spread of M. meleagridis is of little signiﬁcance (except for contamination via
artiﬁcial insemination) compared to vertical egg transmission. Embryos become infected following
ingestion or inhalation of infected amniotic ﬂuid and infection of the female reproductive tract occurs
during embryonic development (Rhoades, 1971; Chin, 2013).
Very few organisms are necessary to produce infection: inoculation of embryos with as few as
0.685 CFU resulted in air-sac lesions (Rhoades, 1971).
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
M. gallisepticum
No transmission from animals to humans reported for M. gallisepticum. This bacterium was only
shown to be able to survive in the human nasal passage for 24 h (Christensen et al., 1994).
M. meleagridis
No transmission from animals to humans have been reported for M. meleagridis.
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
M. gallisepticum
Since recent precise ﬁeld epidemiological studies on M. gallisepticum are missing, the incidence
cannot be calculated.
Airborne transmission leads to highly variable infection rate depending on the strain infectivity and
virulence. Some strains spread very quickly by contact (100% of birds positive in a na€ıve ﬂock after
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4 weeks) while others spread very slowly (with a serologic response after 16 weeks). Variant atypical
strains have been isolated, producing poor or none antibody response.
Horizontal transmission of M. gallisepticum from very few infected eggs and 1-day-old chicks is
likely to involve entire ﬂocks that receive any infected chicks (Raviv and Ley, 2013).
M. meleagridis
Since recent precise epidemiological studies are missing, the incidence cannot be calculated.
Airborne transmission usually leads to a high infection rate (up to 100% of birds), resulting in a genital
localisation in 5% of young birds, but not in adults.
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
M. gallisepticum
Feberwee et al. (2005) described an experimental model to quantify M. gallisepticum horizontal
transmission: R0 was estimated to be greater than 1 and the estimated beta was 0.22 per day.
The egg transmission rate among individual hens may vary considerably under natural conditions.
Under experimental conditions, the highest transmission rates were found during the acute phase of
infection with 25–50% infected eggs 3–6 weeks after challenge. The egg transmission rate then
declined after the acute phase: transmission rates of 3–5% after 8–25 weeks post-infection were
reported (Raviv and Ley, 2013). Egg transmission probably occurs at lower levels during chronic
infections.
Horizontal transmission of M. gallisepticum by direct or indirect contact between one infected bird
and a na€ıve ﬂock can lead to the infection of 100% the birds (development of clinical signs or serologic
response to infection) within 3–19 weeks (Raviv and Ley, 2013).
M. meleagridis
There is no precise information about the transmission rate (beta and R0) for M. meleagridis.
The egg transmission rate among individual turkey hens may vary from 10% to 60%, with variation
during the laying season: transmission starts at low rate at the beginning and reach a maximum at
midseason. Egg transmission does not occur in animals only infected in the upper respiratory tract
(Kumar and Pomeroy, 1969; Chin, 2013). Infected eggs result in a widespread distribution of infection
in young turkeys and increase risk of further vertical transmission.
Insemination with M. meleagridis contaminated semen also plays a major role in infecting the
genital tract of turkey hens and therefore in sustaining the egg-transmission rate during the laying
season (Kumar and Pomeroy, 1969; Chin, 2013).
Egg transmission does not occur in non-infected females reared with infected ones.
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, where the disease is not present in the Union, the risk of its introduction
into the Union
Presence and distribution
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
M. gallisepticum
Control programmes at the breeding ﬂock level, with the availability of M. gallisepticum-free eggs
and 1-day-old chicks or poults, reduce the risk of egg-borne infection and transmission between ﬂocks
by introduction of infected birds (Levisohn and Kleven, 2000; Raviv and Ley, 2013).
Sporadic cases are reported in broilers or meat turkeys in several Member States (MSs) (cases not
published, personal communications from different research laboratories). However M. gallisepticum
may be endemic in some large multiage laying-hen farms (Levisohn and Kleven, 2000) and vaccination
programmes are therefore implemented to reduce clinical signs and losses.
M. meleagridis
No recent cases of infection with M. meleagridis have been published in the Union. Control
programmes at the breeding ﬂock level, with the availability of M. meleagridis-free eggs, reduce the
risk of egg-borne infections.
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Risk of introduction
Parameter 3 – Routes of possible introduction
M. gallisepticum
A route of possible introduction of the disease would be an infection in a chicken or turkey breeder
ﬂock as egg-borne infection is a major route of infection: introduction of birds (males or females)
infected by M. gallisepticum, artiﬁcial inoculation of hens by contaminated semen.
Other routes of introduction would be infection of birds (at any age) by an airborne transmission
from an infected ﬂock nearby, by fomites, or by contaminated wild birds (since peridomestic wild birds
such as magpies or house-sparrows for example can be infected).
M. meleagridis
A route of possible introduction of the disease would be an infection in a turkey breeder ﬂock since
egg-borne infection is the major route of infection: introduction of birds (males or females) infected by
M. meleagridis or artiﬁcial inoculation of hens by contaminated semen.
Another route would be infection of young turkeys (before sexual maturity) by an airborne
transmission from wild birds but this possibility seems highly unlikely.
Parameter 4 – Number of animal moving and/or shipment size
M. gallisepticum
Member States import hatching eggs and day-old chicks from the US and Canada. However, they
apply the European Union (EU) import rules in Regulation (EC) 798/20081 and have equivalent
measures for Mycoplasma in place (see certiﬁcates in that regulation).
M. meleagridis
Turkey production in the EU is concentrated in a small number of MSs. Five countries (Germany,
France, Italy, the UK and Poland) produce more than 80% of all EU turkey meat. The number of
companies in the turkey primary breeding sector is even smaller as only a few companies in a limited
number of MSs are involved (A.V.E.C., 2015). Movements/shipments of animals from non-European
countries are probably not signiﬁcant and subjected to control measures.
Parameter 5 – Duration of infectious period in animal and/or commodity
M. gallisepticum/M. meleagridis
See Section 3.1.1.5 Parameters 1 and 4.
Parameter 6 – List of control measures at border (testing, quarantine, etc.)
M. gallisepticum
Measures concerning M. gallisepticum are described in the Council Directive 2009/158/EC2 and
related import rules in Commission Regulation (EC) No 798/2008 on animal health conditions
governing intra-Community trade in, and imports from third countries of, poultry and hatching eggs;
with the Commission Decision 2011/214/EU3 amending annexes II to IV of this directive:
• The presence of infection must be tested by validated serological and/or bacteriological and/or
molecular tests. The presence of airsacculitis lesions in day-old birds suggests that a
Mycoplasma infection is present and must be investigated.
• Samples for testing for the presence of M. gallisepticum infection must be taken, as
appropriate, from blood, day-old chicks or turkey poults, sperm or swabs taken from the
trachea, the cloaca or air sacs.
1 Commission Regulation (EC) No 798/2008 of 8 August 2008 laying down a list of third countries, territories, zones or
compartments from which poultry and poultry products may be imported into and transit through the Community and the
veterinary certiﬁcation requirements (Text with EEA relevance). OJ L 226, 23.8.2008, p. 1–94.
2 Council Directive 2009/158/EC of 30 November 2009 on animal health conditions governing intra-Community trade in, and
imports from third countries of, poultry and hatching eggs. OJ L 343, 22.12.2009, p. 74–113.
3 2011/214/EU: Commission Decision of 1 April 2011 amending Annexes II to IV to Council Directive 2009/158/EC on animal
health conditions governing intra-Community trade in, and imports from third countries of, poultry and hatching eggs. OJ L 90,
6.4.2011, p. 27–49.
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• Tests for detecting M. gallisepticum must be performed on a representative sample (usually
including 60 animals) in order to allow continuous surveillance of the infection during rearing
and laying, namely just before the start of laying and every 3 months thereafter.
M. meleagridis
Measures concerning M. meleagridis are described in the Council Directive 2009/158/EC on animal
health conditions governing intra-Community trade in, and imports from third countries of, poultry and
hatching eggs; with the Commission Decision 2011/214/EU amending annexes II to IV of this
directive:
• The presence of infection must be tested by validated serological and/or bacteriological and/or
molecular tests. The presence of airsacculitis lesions in day-old turkey poults suggests that a
Mycoplasma infection is present and must be investigated.
• Samples for testing for the presence of M. meleagridis infection must be taken, as appropriate,
from blood, day-old turkey poults, sperm, or swabs taken from the trachea, the choanae,
cloaca or air sacs and in particular for the detection of M. meleagridis samples must be taken
from oviduct and penis of turkeys.
• Tests for detecting M. meleagridis must be performed on a representative sample (usually 60
animals) in order to allow continuous surveillance of the infection during rearing and laying,
namely just before the start of laying and every 3 months thereafter.
Parameter 7 – Presence and duration of latent infection and/or carrier status
M. gallisepticum/M. meleagridis
See Section 3.1.1.5. Parameters 2 and 3.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
M. gallisepticum
Several diagnostic tools are available to detect M. gallisepticum infections:
• Bacteriological isolation and identiﬁcation (Raviv and Ley, 2013): M. gallisepticum can be
isolated on speciﬁc media (commercially available or laboratory-prepared). However, isolation
can be difﬁcult: speciﬁc growth requirements, slow growth of M. gallisepticum, and poor
recovery in case of contamination by other bacteria or bad transport conditions. Isolation is
therefore mainly performed by specialised laboratories and might require up to 3–4 weeks for
detectable growth.
• Serology: Antibodies can be detected from birds hatched from infected eggs in 3 weeks and
from birds infected by contact in 2–3 weeks. Detection is usually performed by rapid serum
agglutination (RSA) or enzyme-linked immunosorbent assay (ELISA). Several commercial
antigens (for RSA) and tests (for ELISA) are available in EU.
• PCR: DNA-based detection has been developed for direct detection of M. gallisepticum. These
techniques are rapid and highly speciﬁc and sensitive, and they allow detection of
M. gallisepticum in contaminated samples or in antibiotic-treated ﬂocks. These tests are
however able to detect both viable and non-viable organisms (except with reverse-
transcriptase PCR tests based on RNA detection (Tan et al., 2014)). Several conventional and
real-time PCR tests have been described (for review see (Raviv and Ley, 2013)). Several PCR
kits for the detection of M. gallisepticum are available in EU.
M. meleagridis
Several diagnostic tools are available to detect M. meleagridis infections:
• Bacteriological isolation and identiﬁcation: like other avian Mycoplasma species, M. meleagridis
can be isolated on speciﬁc media (commercially available or laboratory-prepared). However,
isolation can be difﬁcult: speciﬁc growth requirements, slow growth of M. meleagridis, poor
recovery in case of contamination by other bacteria (especially with cloacal samples) or bad
transport conditions. Isolation is therefore mainly performed by specialised laboratories.
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• Serology: Antibodies can be detected from poults hatched from infected eggs in 3 weeks and
from turkeys infected by contact in 4–5 weeks (Chin, 2013). Detection is usually performed by
RSA (OIE, 2008) or ELISA (Dufour-Gesbert et al., 2001; Chin, 2013). Several commercial
antigens (for RSA) and tests (for ELISA) are available in EU.
• PCR: DNA-based detection has been developed for direct detection of M. meleagridis. These
techniques are rapid, speciﬁc and sensitive, and they allow detection of M. meleagridis in
contaminated samples (such as cloacal swabs) or in antibiotic-treated ﬂocks. These tests are
however able to detect both viable and non-viable organisms. Several conventional PCR tests
and one real-time PCR test have been described (for review see (Chin, 2013)).
Control tools
Parameter 2 – Existence of control tools
M. gallisepticum
Several disease control tools can be used:
• Because M. gallisepticum is egg-transmitted, maintaining commercial ﬂocks free of
M. gallisepticum is only possible by starting with infection-free breeding ﬂocks reared with
adequate biosecurity measures to avoid introduction of the organism (Levisohn and Kleven,
2000). Test and slaughter of M. gallisepticum-positive animals in these ﬂocks is effective for
disease control since most of breeding stocks are free of M. gallisepticum infections;
• Purchase of uninfected eggs (for hatcheries) and birds (for producers) as one the major
transmission route is the vertical one, by egg-borne transmission; infected eggs result in
widespread distribution of infection and increased risk of further vertical or horizontal
transmission;
• All-in/all-out production (to avoid contamination of young birds by older ones in another
building on the same site);
• Biosecurity measures (to avoid contamination of birds by airborne transmission from another
farm or by horizontal transmission by contaminated materials or clothes from another farm);
• Where control of M. gallisepticum infection is more difﬁcult, vaccination of ﬂocks can be
performed (Levisohn and Kleven, 2000; Raviv and Ley, 2013). Vaccination programmes are
applied in commercial laying hen-ﬂocks, but not in broiler ﬂocks (short-lived birds) or turkey
ﬂocks (no commercial vaccine available for the moment). However several studies performed
on different commercial vaccines (inactivated or live-attenuated vaccines) showed that
vaccination can reduce expression of clinical signs and lesions, but cannot prevent colonisation
with a virulent strain (Raviv and Ley, 2013);
• Decrease of the severity of clinical signs and better performances have also been observed
with antimicrobial treatments (for review see (Raviv and Ley, 2013)). However, even if
treatments are able to decrease the bacterial load, persistence of M. gallisepticum has been
described (Raviv and Ley, 2013) even without resistance selection (Reinhardt et al., 2005).
M. meleagridis
Several disease control tools can be used:
• Purchase of uninfected eggs (for hatcheries) and poults (for producers) as the major
transmission route is the vertical one, by egg-borne transmission; infected eggs result in
widespread distribution of infection and increased risk of further vertical transmission;
• All-in/all-out production (to avoid contamination of young birds by older ones in another
building on the same site);
• Biosecurity measures (to avoid contamination of young birds by airborne transmission from
another farm, or by horizontal transmission by contaminated materials or clothes from another
farm);
• Males may warrant special attention as infected males are particularly prone to transmit
infection (M. meleagridis-infected semen transmitted to hens through artiﬁcial insemination);
• Experimental studies showed that administration of antibiotics into eggs either by dipping or by
inoculation were useful methods to reduce the egg-transmission rate and these methods were
used in the past for eradication programmes (for review see Chin, 2013);
• Test and slaughter of M. meleagridis-positive animals may nowadays be effective for disease
control since breeding stocks are free of M. meleagridis infections;
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• Several antibiotics were tested for their in vitro activity against M. meleagridis strains, but
these studies were performed more than 20 years ago with unstandardised methods (Chin,
2013). No recent data is available on antibiotic treatments against M. meleagridis infections.
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
M. gallisepticum
No precise data have been identiﬁed, but M. gallisepticum outbreaks are probably present in nearly
all member states at low level (sporadic cases) because of control programmes in breeder ﬂocks. For
example, the French National Reference Laboratory recorded ﬁve reports of M. gallisepticum infections
in 2016, and isolated two strains from commercial laying hens. But the occurrence is probably
underestimated, especially for backyard poultry and production ﬂocks.
M. meleagridis
No data have been identiﬁed, but the level is probably very low because of control programmes in
breeder ﬂocks since the middle of the 1980s. For example, the French National Reference Laboratory
did not receive any strains of M. meleagridis from France during the last 20 years.
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
M. gallisepticum
In broilers, M. gallisepticum infections lead to retarded growth with a reduction in weight gain up
to 20–30% and to a 10–20% decrease in food conversion efﬁciency. Clinical signs and lesions are also
source of 10–20% of condemnations or downgrading of carcasses in slaughterhouses (Stipkovits and
Kempf, 1996).
In breeders and laying hens, M. gallisepticum infection may be responsible for a 10–20% decrease
in egg production.
Mortality in broilers may range from 1% in uncomplicated disease to as much as 30% in
complicated outbreaks with other bacteria or viruses.
M. meleagridis
During the early 1980s (when prevalence of M. meleagridis infections was very high in all turkey
breeders), the cost to the US turkey industry resulting from reduced hatchability due to M. meleagridis
and the cost of egg treatment to reduce egg-borne transmission of the pathogen was estimated at
$9.4 million per year (Carpenter et al., 1981).
Egg-transmission rates may vary from 10% to 60% (between hens and during the laying season),
with a loss of hatchability of 5–6% of M. meleagridis-infected fertile eggs (late mortality between 25
and 28 days) (Chin, 2013).
Air-sacculitis, one of the major cause of condemnation of turkeys in the 1960s, was reported to
rate 10–25% in M. meleagridis-infected ﬂocks.
Skeletal abnormalities observed in 5–10% of the poults hatched from infected eggs can also lead to
condemnation at slaughter or to reduced growth rates.
In case of a M. meleagridis infection in a breeder ﬂock, even at a low level, semen and eggs cannot
be sold (because of control programmes against M. meleagridis infections).
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
M. gallisepticum
No zoonotic cases have been recorded. M. gallisepticum infects exclusively avian host species as
listed in Section 3.1.1.1.
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M. meleagridis
No zoonotic cases have been recorded. M. meleagridis infects a very narrow range of exclusively
avian host species as listed in Section 3.1.1.1.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
M. gallisepticum
Infection with M. gallisepticum may have a wide diversity of clinical manifestations. Infection alone
is often mild to subclinical in chickens, but may cause respiratory disease in turkeys (sinusitis,
respiratory distress, listlessness) (Stipkovits and Kempf, 1996; Levisohn and Kleven, 2000; Raviv and
Ley, 2013). Feed consumption is reduced and birds lose weight. In commercial layer, ﬂocks egg
production is decreased and maintained at a lowered level. Intercurrent infections (E. coli, avian
viruses) may cause severe outbreaks with high morbidity and mortality. Partial to complete closure of
the eyes sometimes results from severe swelling of the sinuses.
A high level of morbidity and mortality was also observed in wild house ﬁnches in the USA with
severe conjunctivitis (Raviv and Ley, 2013).
Respiratory distress and intercurrent infections causing morbidity and mortality can cause pain and
distress to infected animals and therefore decrease their welfare.
M. meleagridis
M. meleagridis do not induce signiﬁcant clinical signs and commonly occur as a silent infection in
adult turkeys (Chin, 2013). Young turkeys are more sensitive than older birds to M. meleagridis
infections, with development of air-sacculitis, but respiratory signs are rarely observed. M. meleagridis-
induced airsacculitis can be more severe in case of co-infection with Mycoplasma iowae or E. coli
(Chin, 2013) and therefore decrease animal welfare.
Severe clinical signs are mainly associated with egg-borne infection and are observed in young
birds: irreversible skeletal abnormalities such as bowing, twisting and shortening of the tarso-
metatarsal bones, wry necks and hock joint swelling (Cardona and Bickford, 1993; Stipkovits and
Kempf, 1996; Chin, 2013). These signs can lead to reduction in growth rate, may cause pain to
animals and decrease animal welfare. Moreover, they can also lead to indirect mortality by cannibalism
of affected birds.
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
M. gallisepticum
Very little information is available on M. gallisepticum infections in endangered wild bird species.
Hagen et al. (2002) found a low seroprevalence against M. gallisepticum in lesser prairie-chickens in
Kansas but could not rule out the hypothesis of a non-speciﬁc reaction. Straub et al. (2015) reported a
1% seroprevalence for M. gallisepticum in free-ﬂying Californian condors and a 57% seroprevalence
for captive birds. However, these authors did not report observation of clinical signs on these birds. No
other wild endangered species affected by M. gallisepticum infections were reported.
M. meleagridis
No wild endangered species affected by M. meleagridis infections. As seen in Section 3.1.1.1
Parameters 1 and 5, very few studies evidenced a M. meleagridis infection in wild species, and if so,
without clinical signs.
Parameter 2 – Mortality in wild species
M. gallisepticum
According to several studies, M. gallisepticum can cause mortality in house ﬁnches (Luttrell et al.,
2001; Sydenstricker et al., 2006; Raviv and Ley, 2013). Other species were found contaminated with
sometimes expression of clinical signs, but without marked mortality.
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M. meleagridis
No mortality recorded in wild species as M. meleagridis is very host speciﬁc and do not lead to
direct mortality (except late embryo mortality in turkey eggs).
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
M. gallisepticum
This pathogen is able to persist in the environment for several hours to several days depending on
substrate, pH, temperature and humidity (see Section 3.1.1.5 Parameter 4). Contamination of wild
na€ıve birds by M. gallisepticum-infected fomites (bird feeders for example) was reported (Dhondt
et al., 2007).
M. meleagridis
The pathogen is probably able to persist in the environment for several days like other avian
Mycoplasma species (see Section 3.1.1.5 Parameter 4), but without causing mortality in wildlife.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
They are not listed.
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
M. gallisepticum
Diagnostic tools for M. gallisepticum are listed in the OIE terrestrial manual: RSA tests, isolation by
culture and one PCR test are described in detail (OIE, 2008). The ELISA technology is not described in
detail since several MG kits are available commercially.
Different antigens (for RSA) or kits (PCR, real-time PCR, ELISA) are used in Europe for the
detection of M. gallisepticum in diagnostic and research laboratories.
M. meleagridis
Diagnostic tools for M. meleagridis are not listed in the OIE terrestrial manual but RSA tests and
isolation by culture can be used in the same conditions as those described for M. gallisepticum and
Mycoplasma synoviae (OIE, 2008).
No PCR or ELISA tests is known to have been ofﬁcially/internationally recognised, but different tests
or kits are used for the detection of M. meleagridis in diagnostic and research laboratories (for review
see Chin, 2013).
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
M. gallisepticum/M. meleagridis
Serological procedures are useful for ﬂock monitoring in M. gallisepticum/M. meleagridis monitoring
programmes: screening for infection is usually accomplished by RSA test or by ELISA. RSA test is
highly efﬁcient in detecting immunoglobulin M (IgM) antibodies, which is the ﬁrst class of
immunoglobulins produced in response to infection (ﬁrst positive birds 1–2 weeks after infection),
before IgY which are detected by RSA and ELISA (3–4 weeks after infection). Moreover, RSA test is
quick, relatively inexpensive and sensitive. However, non-speciﬁc reactors may occur in some ﬂocks
infected with M. synoviae (due to cross-reactive antigens) or recently vaccinated with oil-emulsion
vaccines. RSA positive results have therefore to be conﬁrmed either by ELISA, culture or PCR tests.
ELISA tests are in general slightly less sensitive but more speciﬁc than RSA tests (no cross-reaction).
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Isolation and identiﬁcation of the bacterium is the reference standard for M. gallisepticum/
M. meleagridis diagnosis. However, culture is not a sensitive method, it is time-consuming and cannot
be performed by non-specialised laboratories. PCR tests, which are highly sensitive (less than 1 CFU/ml
for the most sensitive ones) and speciﬁc, represent a rapid alternative (positive results in hours instead
of days or weeks) to traditional culture methods and are used to conﬁrm serological results. However,
PCR results should be interpreted with caution since detection of M. gallisepticum/M. meleagridis DNA
represent the presence of viable organisms.
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
M. gallisepticum
Samples for testing for the presence of M. gallisepticum infection must be taken, as appropriate,
from blood or vitellus (for RSA and ELISA tests), day-old chicks or turkey poults, sperm or swabs
(or pieces of tissue) taken from trachea, choanae, cloaca, air sacs, oviduct and penis (for bacterial
isolation or PCR tests).
M. meleagridis
Samples for testing for the presence of M. meleagridis infection must be taken, as appropriate,
from blood (for RSA and ELISA tests), day-old turkey poults, sperm, or swabs (or pieces of tissue)
taken from trachea, choanae, cloaca, air sacs, oviduct and penis of turkeys (for bacterial isolation or
PCR tests).
3.1.4.2. Article 7(d)(ii) Vaccination
Availability
Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)
M. gallisepticum
Vaccination may be the most practical option in infected multiage commercial layer facilities when
biosecurity measures fail to prevent the infection.
Both killed vaccines (bacterins) and live vaccines are currently in commercial use worldwide
(Whithear, 1996; Levisohn and Kleven, 2000; Raviv and Ley, 2013; Jacob et al., 2014).
Bacterins usually contain an oil emulsion adjuvant to stimulate the bird’s immune system. They
have the advantage to be non-infectious but they are expensive to use (requiring large amounts of
antigen and necessity of handling birds individually for intramuscular administration of the vaccine).
The F strain (Poulvac® Myco F, Zoetis for example) is considered to be of low to moderate virulence
and transmissibility, but can induce respiratory signs in broilers and in turkeys. It persists in the upper
respiratory tract of chickens for the ﬂock’s life and was shown to be transmitted between ﬂocks.
The 6/85 strain (Nobilis MG 6/85, MSD Animal Health for example) is a modiﬁed M. gallisepticum
strain which is avirulent for chickens and turkeys, and is not easily transmitted horizontally. This
vaccine is authorised for use in the EU.
The ts-11 M. gallisepticum strain (Vaxsafe® MG strain ts-11, Bioproperties for example) was
developed by chemical mutagenesis and was selected as a temperature-sensitive mutant. It is
avirulent for chickens and turkeys, has a low propensity to spread from bird to bird and persists for
the life of the ﬂock in the upper respiratory tract.
Because of their superior safety characteristics of avirulence and low potential for spread to nearby
ﬂocks, both ts-11 and 6/85 vaccines are considered to be preferable to F strain.
M. meleagridis
No vaccine available on the market.
Parameter 2 – Availability/production capacity (per year)
M. gallisepticum
All vaccine strains described above are available, but only the 6/85 strain is authorised in EU and
currently used in commercial layer farms. This vaccine strain is commercialised by MSD Animal Health
(Intervet).
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Autologous vaccines (bacterins) are also used in commercial laying ﬂocks in EU, but their
production is limited since large amounts of strains are necessary for the vaccination of one ﬂock.
Several laboratories in EU are specialised in production of these vaccines.
M. meleagridis
Not applicable.
Effectiveness
Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to
disease)
M. gallisepticum
Inactivated M. gallisepticum bacterins have been shown to provide limited protection against ﬁeld
strains, to reduce the shedding of M. gallisepticum, but not to reduce the horizontal transmission of
the bacterium between laying hens.
Vaccination with the F strain has been shown to reduce egg production losses, mortality and
antibiotic requirement in commercial layers and to induce resistance against infection by wild-type
strains or challenge infection. F strain can displace endemic strains but can also maintain itself in
multiage ﬂocks after vaccination is discontinued.
Ts-11 and 6/85 strains are less protective, but are able to reduce losses associated with M. gallisepticum
wild-type infections and confer signiﬁcant protection against development of air-sac lesions.
M. meleagridis
Not applicable.
Parameter 4 – Duration of protection
M. gallisepticum
For all vaccine strains, immunity develops within 3–4 weeks.
F strain- and ts-11-vaccinated birds remain carriers of the strain for life and immunity lasts through
the laying season.
The 6/85 strain can be detected in the upper respiratory tract for 4–8 weeks after vaccination and
immunity was shown to last for at least 24 weeks.
M. meleagridis
Not applicable.
Feasibility
Parameter 5 – Way of administration
M. gallisepticum
Bacterins are administered by intramuscular injections.
The F strain can be administered at 8–14 weeks of age by several routes including intraocular and
intranasal, and by coarse spray. Vaccination may induce mild respiratory signs and lesions.
The recommended route of administration for the 6/85 strain is by aerosol spray from 6 weeks of
age. Two vaccinations can be performed (6 and 16 weeks) to improve efﬁcacy of vaccination.
The ts-11 strain is administered by eye drop between 4 and 16 weeks of age.
M. meleagridis
Not applicable.
3.1.4.3. Article 7(d)(iii) Medical treatments
Availability
Parameter 1 – Types of drugs available on the market
M. gallisepticum
Several antibiotics can be used to treat mycoplasmal infections: macrolides, lincosamides,
aminoglycosides, tetracyclines, ﬂuoroquinolones and pleuromutilins.
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M. meleagridis
Several antibiotics can be used to treat mycoplasmal infections: macrolides, lincosamides,
aminoglycosides, tetracyclines, ﬂuoroquinolones and pleuromutilins. Several antibiotics were tested for
their in vitro activity against M. meleagridis strains, but these studies were performed more than
20 years ago with unstandardised methods (Chin, 2013).
Parameter 2 – Availability/production capacity (per year)
M. gallisepticum/M. meleagridis
All these antibiotic families are produced to treat animals against several diseases, including other
mycoplasma infections and their availability should not be a problem.
Effectiveness
Parameter 3 – Therapeutic effects on the ﬁeld (effectiveness)
M. gallisepticum
Most strains of M gallisepticum are susceptible in vitro to a number of broad-spectrum antibiotics,
including macrolides, tetracyclines, ﬂuoroquinolones and others but not to penicillins or those that act
on the cell wall (intrinsic resistance of the class Mollicutes) (Levisohn and Kleven, 2000; Bebear and
Kempf, 2005; Raviv and Ley, 2013). However, M. gallisepticum can develop resistance and cross-
resistance to antibiotics commonly used in ﬁeld conditions (Reinhardt et al., 2002; Bebear and Kempf,
2005).
Tylosin or tetracyclines have been commonly used to reduce egg transmission or as prophylactic
treatment to prevent respiratory disease in broilers and turkeys (Levisohn and Kleven, 2000; Raviv and
Ley, 2013). Antibiotics may alleviate the clinical signs and lesions, reduce egg transmission and
production losses, but do not eliminate infection. Several studies have shown persistence of
M. gallisepticum after antimicrobial treatments (Raviv and Ley, 2013), but this persistence is not
always linked to antibiotic resistance (Reinhardt et al., 2005). Medication should not be regarded be as
a long-term solution to the problem, but only as a method for short-term amelioration of signs and
economic effect in poultry ﬂocks.
M. meleagridis
No recent data is available on antibiotic treatments against M. meleagridis infections. However,
avian mycoplasmas are usually susceptible to macrolides, lincosamides, aminoglycosides, tetracyclines,
ﬂuoroquinolones and pleuromutilins (Hannan, 2000; Wang et al., 2001; Gerchman et al., 2008). Recent
studies evidenced M. gallisepticum and Mycoplasma synoviae resistant strains (Gerchman et al., 2008,
2011; Lysnyansky et al., 2013, 2015) and development of resistance was also recorded in vitro for
M. gallisepticum, M. synoviae and M. iowae (Gautier-Bouchardon et al., 2002), and in vivo for
M. gallisepticum and M. synoviae (Le Carrou et al., 2006; Gerchman et al., 2011).
Antibiotic treatments against susceptible strains of avian mycoplasmas lead to a decrease or
disappearance of clinical signs but persistence of mycoplasmas is often observed (Reinhardt et al.,
2005; Le Carrou et al., 2006).
Feasibility
Parameter 4 – Way of administration
M. gallisepticum
Antibiotic treatments are usually administered via drinking water (for ﬂock treatments).
M. meleagridis
Antibiotic treatments are usually administered in drinking water (for ﬂock treatments), but for
M. meleagridis, as an egg-borne infection, treatments can also be administered by egg-dipping or
inoculation into eggs (Chin, 2013).
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3.1.4.4. Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 – Available biosecurity measures
M. gallisepticum/M. meleagridis
Most of breeder ﬂocks have strong biosecurity measures such as:
• All-in/all-out production, allowing time for cleaning and disinfection of buildings and equipment
between two ﬂocks;
• In multiage farms, trafﬁc through poultry houses should always ﬂow from younger to older
birds;
• Introduction of new animals, eggs or semen (potentially infected, healthy carrier) should be
avoided without testing and/or quarantine;
• Visitors should be kept to a minimum and any visitors should wear protective covering such as
boots, coveralls and headgear after hand-washing;
• Visits to other poultry farms should be limited unless absolutely necessary;
• Disinfection of transport trucks and loadout materials;
• All animals should be kept out of poultry houses (cats, dogs, wild animals and birds, insects)
and sound rodent and pest control should be implemented;
• If possible, breeder farms should be far enough from production farms to avoid airborne
contaminations;
• Environment of birds should be maximised (dry litter, good ventilation and temperature) to
avoid development of diseases.
Requirements for establishments (Article 6 and conditions in Annex II) do not only apply to
breeding poultry but also to productive poultry when traded between MSs.
Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
M. gallisepticum
These biosecurity measures have been applied for more than 30 years, together with control
programmes (regularly performed diagnostic tests) to avoid contamination of chicken and turkey
breeder ﬂocks by M. gallisepticum after eradication programmes implemented in the 1980s. Since only
sporadic cases of M. gallisepticum infections are reported in EU, these biosecurity measures are
effective in preventing introduction in breeder ﬂocks.
M. meleagridis
These biosecurity measures have been applied for more than 30 years, together with control
programmes (regularly performed diagnostic tests) to avoid contamination of turkey breeder ﬂocks by
M. meleagridis after eradication programmes in the 1980s. The lack of data about M. meleagridis
prevalence in EU is a good indicator of the effectiveness of these measures.
Feasibility
Parameter 3 – Feasibility of biosecurity measures
M. gallisepticum/M. meleagridis
Most of these biosecurity measures are easy to put in place in all farms. All European breeder ﬂocks
provide M. gallisepticum/M. meleagridis-free eggs.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
M. gallisepticum
The only restriction movement measure available for M. gallisepticum is applied for breeder ﬂocks
and hatcheries (as described in the Council Directive 2009/158/EC on animal health conditions):
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positive ﬂocks cannot sell animals or eggs, and hatcheries have to buy M. gallisepticum-free certiﬁed
eggs.
M. meleagridis
The only restriction movement measure available for M. meleagridis is applied for breeder ﬂocks (as
described in the Council Directive 2009/158/EC on animal health conditions): positive ﬂocks cannot sell
animals or eggs.
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread
M. gallisepticum
Restriction of animal and egg movement for M. gallisepticum positive ﬂocks is preventing vertical
spread of disease since this measure prevents contamination of farms free of M. gallisepticum.
However, M. gallisepticum can also be readily transmitted horizontally by contaminated birds and
fomites (Stipkovits and Kempf, 1996; Raviv and Ley, 2013). This transmission is not entirely taken into
account in the current measures since surveillance measures and restriction of animal movement are
not compulsory in production ﬂocks. Sporadic cases recorded in breeder ﬂocks or production ﬂock may
ﬁnd their origin in cases from backyard poultry or production ﬂocks (commercial laying hen ﬂocks for
example) of unknown status for M. gallisepticum.
M. meleagridis
Restriction of animal and egg movement for M. meleagridis-positive ﬂocks is preventing disease
spread since this measure prevents contamination of farms free of M. meleagridis. This mycoplasmal
infection is mainly transmitted vertically not only through contaminated egg, but also by contaminated
poults (young turkeys being more sensitive to infection than adults).
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
M. gallisepticum
This measure is already applied in case of outbreaks of M. gallisepticum infection in breeder ﬂocks.
Since this disease is only sporadically observed nowadays, it is not a highly infectious disease and it is
mainly transmitted vertically, this measure should apply to very few ﬂocks if the outbreak is detected
early by regularly performed diagnostic tests.
M. meleagridis
This measure is already applied in case of outbreaks of M. meleagridis infection. As this disease is
rarely observed nowadays, is not a highly infectious disease and is mainly transmitted vertically, this
measure should apply to very few ﬂocks if the outbreak is detected early by regularly performed
diagnostic tests.
3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animals
M. gallisepticum/M. meleagridis
Since M. gallisepticum/M. meleagridis is not a zoonotic and highly contagious agent, infected birds
can be killed in slaughterhouses and killed animals can enter human consumption if they don’t harbour
clinical signs or lesions.
Animals may also be killed on farm (electrical stunning and bleeding in trucks, CO2 culling in barns,
or lethal injection).
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Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping
spread of the disease
M. gallisepticum/M. meleagridis
In general, Mycoplasma infections, once established, are known to persist for all the ﬂock’s life,
even after antibiotic treatments. Killing animals of positive ﬂocks is a good measure to remove this
permanent source of infection for other lots or ﬂocks. However, since M. gallisepticum/M. meleagridis
infection is not a highly infectious disease (like avian inﬂuenza for example), massive culling of birds is
not necessary. Killing can be applied at farm level or at ﬂock level (within a farm) if good biosecurity
measures can ensure the non-spread of M. gallisepticum to other ﬂocks in or outside the farm.
Feasibility
Parameter 3 – Feasibility of killing animals
M. gallisepticum
This measure is already applied in case of outbreaks of M. meleagridis infection in breeder ﬂocks.
As this disease is rarely observed in theses ﬂocks, this measure should apply to very few ﬂocks if the
outbreak is detected early by regularly performed diagnostic tests.
It would be more difﬁcult to apply this measure to production ﬂocks and backyard poultry ﬂocks to
remove all sources of infection. The ﬁrst step would be to implement an epidemiological survey to
have recent data about the real prevalence of M. gallisepticum infections in poultry ﬂocks in the EU.
M. gallisepticum may be endemic in several multiage commercial laying hen farms.
M. meleagridis
This measure is already applied in case of outbreaks of M. meleagridis infection. As this disease is
rarely observed nowadays and is mainly transmitted vertically, this measure should apply to very few
ﬂocks if the outbreak is detected early by regularly performed diagnostic tests.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Availability
Parameter 1 – Available disposal option
M. gallisepticum
Since M. gallisepticum is not a zoonotic and highly contagious agent, adult infected birds can be
killed in slaughterhouses and carcasses of birds without clinical signs or lesions can enter human
consumption.
Infected eggs and day-old birds should be destroyed.
M. meleagridis
Since M. meleagridis is not a zoonotic and highly contagious agent, adult infected turkeys can be
killed in slaughterhouses and carcasses can enter human consumption if birds do not harbour clinical
signs or lesions.
Infected eggs and poults should be destroyed.
Effectiveness
Parameter 2 – Effectiveness of disposal option
M. gallisepticum/M. meleagridis
These disposal options are effective in eliminating the risk of spread of the disease to other ﬂocks by
removing one of the major sources of transmission (egg-borne and airborne, or by artiﬁcial insemination).
Feasibility
Parameter 3 – Feasibility of disposal option
M. gallisepticum
These disposal options are already applied in ﬁeld conditions in case of a M. gallisepticum outbreak
in breeder ﬂocks (chicken and turkeys) in EU.
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M. meleagridis
These disposal options are already applied in ﬁeld conditions in case of a M. meleagridis outbreak
in EU.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
M. gallisepticum
Most of biosecurity measures are already implemented in breeder farms, even in production farms
(broilers, meat turkeys, laying hens).
Vaccination cannot be applied for broilers (short life) and turkeys (no commercial vaccine available)
as already seen in Section 3.1.4.2. Vaccination is not performed in breeder ﬂocks to avoid RSA and
ELISA positive reaction (due immunological response to the vaccine strain) during surveillance
programmes. Vaccination is performed in commercial layer ﬂocks, especially with multiage systems.
The MG 6/85 vaccine strain is at an average of €100 for 1,000 doses.
Treatments with antibiotics do not seem to be the best option for this disease as it will not ensure
the non-transmission of the infection by the vertical way (even if antibiotic treatment will lower clinical
signs and improve ﬂock’s performance, it is very unlikely that adult birds will not remain carriers and
sources of infection). Medication is just a method for short-term amelioration of signs and economic
effect in poultry ﬂocks. Commercial layer ﬂocks can only be treated with oxytetracycline or tylosine: a
treatment with oxytetracyclin is less expensive than with Tylan (5–10€ vs 50–60€ for 200 L of drinking
water).
M. meleagridis
Most of biosecurity measures are already implemented in farms, even in production farms.
As already seen in Sections 3.1.4.2 and 3.1.4.3, there are no vaccine available and treatments with
antibiotics do not seem to be the best option for this disease as it will not ensure the non-transmission
of the infection by the vertical way (even if antibiotic treatment will lower clinical signs, it is very
unlikely that adult birds will not remain carriers and sources of infection).
Parameter 2 – Cost of eradication (culling, compensation)
M. gallisepticum
Eradication programmes were applied more than 30 years ago when M. gallisepticum infections
occurred in many chicken and turkey ﬂocks. Culling is now just implemented in M. gallisepticum
positive breeder farms to avoid disease spread to production farms and other breeder farms and cost
will be therefore limited.
If a M. gallisepticum infection is detected in adult chickens or turkeys, these birds can be sent to
slaughterhouses and their carcasses can enter human consumption (if no clinical signs or lesions). The
cost of eradication in this case should mainly take into account the losses due to the non-production of
hatching eggs by the killed adults. To give an idea of compensations that could be paid to farmers, the
example of Salmonella infections can be taken: each European country ﬁxed the amount of
compensation depending on the age of the animals at the date of disposal and type of animal (future
breeding or breeding chickens or turkeys, males or females, for meat or commercial egg production).
For France, see the NOR AGRG0927983A (turkeys), NOR AGRG0803839A (broilers) and the NOR
AGRG0803847A (laying hens) decrees as examples on www.legifrance.gouv.fr.
M. meleagridis
Eradication programmes were applied more than 30 years ago when M. meleagridis infections
occurred in almost all turkey ﬂocks. Culling is now just implemented in M. meleagridis-positive breeder
farms to avoid disease spread to production farms and other breeder farms and cost will be therefore
limited.
If a M. meleagridis infection is detected in adult turkeys, these birds can be sent to
slaughterhouses and their carcasses (without clinical signs or lesions) can enter human consumption.
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The cost of eradication in this case should mainly take into account the losses due to the
non-production of hatching eggs by the killed adults.
Parameter 3 – Cost of surveillance and monitoring
M. gallisepticum
The Council Directive 2009/158/EC and the Commission Decision 2011/214/EU ﬁxed the conditions
for surveillance and monitoring of M. gallisepticum infections in chicken and turkey ﬂocks: 60 samples
per ﬂock just before the start of the laying period and every 3 months thereafter, tested by validated
serological, bacteriological or molecular tests.
The average costs per sample of the various analyses are: 0.30–1€ for RSA tests, 2–3€ for ELISA,
7–20€ for PCR (depending if samples are pooled per 3 or not) and 30–50€ for isolation by culture and
identiﬁcation by PCR.
M. meleagridis
The Council Directive 2009/158/EC and the Commission Decision 2011/214/EU ﬁxed the conditions
for surveillance and monitoring of M. meleagridis infections in turkey ﬂocks: 60 samples per ﬂock just
before the start of the laying period and every 3 months thereafter, tested by validated serological,
bacteriological or molecular tests.
The average costs per sample of the various analyses are: 0.75–1€ for RSA tests, 2–3€ for ELISA,
7–20€ for PCR (depending if samples are pooled per 3 or not) and 30–50€ for isolation by culture and
identiﬁcation by PCR.
Parameter 4 – Trade loss (bans, embargoes, sanctions) by animal product
M. gallisepticum/M. meleagridis
As M. gallisepticum is not zoonotic and not highly infectious, sanctions are just applied at the farm
level (eggs and birds from a M. gallisepticum/M. meleagridis positive farm cannot be sold and
exported) and not at the country level.
Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to
business amount of the sector)
M. gallisepticum
M. gallisepticum is considered as the most pathogenic and economically signiﬁcant mycoplasmal
pathogen of poultry with condemnation at slaughter, downgrading of carcasses, reduced feed and egg
production efﬁciency, increased medication costs (Stipkovits and Kempf, 1996; Raviv and Ley, 2013).
Only few American studies tried to evaluate the real economic impact of this pathogen. The annual
economic impact of M. gallisepticum infections in the USA was estimated between $118 and
150 million for the layer industry alone in 1994 (Evans et al., 2005).
Animal products mainly affected by a M. gallisepticum outbreak are hatching eggs (in breeder
ﬂocks), broilers and meat turkeys and the proportion of commercial egg produced by hens in layer
farms. Mohammed et al. in 1987 estimated that an M. gallisepticum-infected layer ﬂock without
treatment or vaccination produced 12 fewer eggs per hen in the ﬁrst cycle than an uninfected ﬂock
(Mohammed et al., 1987).
With the monitoring and control programmes, losses should be restricted to a few numbers of
breeder ﬂocks (outbreak cases mainly due to airborne infection by fomites or contaminated ﬂocks
nearby).
M. meleagridis
Animal products mainly affected by a M. meleagridis outbreak are hatching eggs. But with the
surveillance and monitoring programmes, losses should be restricted to a few numbers of ﬂocks.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
M. gallisepticum/M. meleagridis
Disease prevention and control measures are already implemented in the EU. Since the impact of a
M. gallisepticum/M. meleagridis outbreak will not have huge consequences as for avian inﬂuenza for
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example in terms of culling and restriction of animal movements, these measures should not pose a
problem of societal acceptance.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
M. gallisepticum
Control measures are already applied in chicken and turkey breeder ﬂocks and do not have welfare
impact on chickens, turkeys or other domestic animals. However, attention should be paid to prevent
distress and pain to animals, especially for the manipulation of turkey breeders in case of culling on
farm: manipulation of heavy animals by legs or wings can be painful and deleterious.
M. meleagridis
Control measures are already applied in turkey breeder ﬂocks and do not have signiﬁcant welfare
impact on turkeys or other domestic animals. However, attention should be paid to prevent distress
and pain to animals, especially for the manipulation of turkey breeders in case of culling on farm:
manipulation of heavy animals by legs or wings can be painful and deleterious.
Parameter 2 – Wildlife depopulation as control measure
M. gallisepticum/M. meleagridis
Not applicable.
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
M. gallisepticum
Treatments with antibiotics are not the best option for the control of this disease as it will not
ensure the non-transmission of the infection by the vertical way and because antibiotic treatment does
not completely eliminate M. gallisepticum infection in a ﬂock (persistence at low level in the ﬂock and
possible re-emergence of the mycoplasma after a stress, a vaccination or a concomitant infection).
However, antibiotics are used in production ﬂocks in case of an outbreak with clinical signs and lesions
and residuals could therefore be found in environmental compartments (soils and water contaminated
by manure from these infected ﬂocks).
M. meleagridis
Treatments with antibiotics are not the best option for the control of this disease as it will not
ensure the non-transmission of the infection by the vertical way. Possible residuals of antibiotics in
environmental compartments would therefore be limited in case of an outbreak.
Biodiversity
Parameter 2 – Mortality in wild species
M. gallisepticum/M. meleagridis
Not applicable.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about avian mycoplasmosis (M. gallisepticum, M. meleagridis) (Table 1). The expert judgement was
based on Individual and Collective Behavioural Aggregation (ICBA) approach described in detail in the
opinion on the methodology (EFSA AHAW Panel, 2017). Experts have been provided with information
of the disease fact-sheet mapped into Article 5 criteria (see supporting information, Annex A), based
on that the experts indicate their Y/N or ‘na’ judgement on each criterion of Article 5, and the
reasoning supporting their judgement.
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The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
3.2.1. Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Table 2). The proportion of Y, N or na answers are reported, followed by
the list of different supporting views for each answer.
Reasoning supporting the judgement
Supporting Yes:
• Based on the current situation, there is low prevalence, mortality and morbidity, and control
measures in place. There may be a potential sporadic occurrence of M. gallisepticum.
• It is reported that M. gallisepticum infections have a worldwide distribution. They resulted in
important ﬂock health problems before implementation of control programmes. Egg-transmission
rates may vary from 10% to 60%, with a loss of hatchability of 5–6% of M. meleagridis-infected
fertile eggs. Air-sacculitis was reported in 10–25% of M. meleagridis-infected ﬂocks, and skeletal
abnormalities were observed in 5–10% of the chicks hatched from infected eggs.
Table 2: Outcome of the expert judgement related to criterion 5 B(iii)
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
B(iii) The disease causes or could cause a signiﬁcant negative economic
impact affecting agriculture or aquaculture production in the Union
NC 83 17 0
NC: non-consensus; number of judges: 12.
Table 1: Outcome of the expert judgement on the Article 5 criteria for avian mycoplasmosis
(Mycoplasma gallisepticum, M. meleagridis)
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof exist in
the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due to
its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective and
proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal health,
or poses or could pose a signiﬁcant risk to public health due to its zoonotic character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger to
public and/or animal health in the Union
N
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
NC
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for the
purpose of bioterrorism
N
B(v) The disease has or could have a signiﬁcant negative impact on the environment, including
biodiversity, of the Union
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
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Supporting No:
• Although theoretically possible, it is unlikely that general biosecurity in the industry would drop
to levels to cause a signiﬁcant negative economic impact in the EU.
3.2.2. Outcome of the assessment of avian mycoplasmosis (M. gallisepticum,
M. meleagridis) according to criteria of Article 5(3) of the AHL on its
eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 1, avian
mycoplasmosis (M. gallisepticum, M. meleagridis) complies with all criteria of the ﬁrst set and with one
criterion of the second set, therefore it is considered eligible to be listed as laid down in Article 5 of the
AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about avian mycoplasmosis (M. gallisepticum, M. meleagridis)
(Tables 3–7). The expert judgement was based on ICBA approach described in detail in the opinion on
the methodology. Experts have been provided with information of the disease fact-sheet mapped into
Article 9 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or
‘na’ judgement on each criterion of Article 9, and the reasoning supporting their judgement. The
experts decided to assess some Article 9 criteria separately for the Mycoplasma pathogens, on the
basis of the evidence available. In this case, in Tables 3, 4 and 5, the outcome of the assessment is
reported by pathogen. The minimum number of judges in the judgement was 9. The expert
judgement was conducted as described in the methodological opinion (EFSA AHAW Panel, 2017). For
details on the interpretation of the questions, see Appendix B of the methodological opinion (EFSA
AHAW Panel, 2017).
Table 3: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for avian mycoplasmosis (Mycoplasma gallisepticum,
M. meleagridis) (CI = current impact; PI = potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final outcome
M. gallisepticum M. meleagridis
1 The disease is not present in the territory of the Union OR
present only in exceptional cases (irregular introductions) OR
present in only in a very limited part of the territory of the
Union
NC NC
2.1 The disease is highly transmissible N
2.2 There be possibilities of airborne or waterborne or vector-borne
spread
na Y
2.3 The disease affects multiple species of kept and wild animals
OR single species of kept animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant
mortality rates
N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant
consequences on public health, including epidemic or pandemic
potential OR possible signiﬁcant threats to food safety
N
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4 (CI) The disease has a signiﬁcant impact on the economy of the
Union, causing substantial costs, mainly related to its direct
impact on the health and productivity of animals
N
4 (PI) The disease has a signiﬁcant impact on the economy of the
Union, causing substantial costs, mainly related to its direct
impact on the health and productivity of animals
Y NC
5(a)
(CI)
The disease has a signiﬁcant impact on society, with in
particular an impact on labour markets
N
5(a)
(PI)
The disease has a signiﬁcant impact on society, with in
particular an impact on labour markets
N
5(b)
(CI)
The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
N
5(b)
(PI)
The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
Y NC
5(c)
(CI)
The disease has a signiﬁcant impact on the environment, due
to the direct impact of the disease OR due to the measures
taken to control it
N
5(c)
(PI)
The disease has a signiﬁcant impact on the environment, due
to the direct impact of the disease OR due to the measures
taken to control it
N
5(d)
(CI)
The disease has a signiﬁcant impact on a long-term effect on
biodiversity or the protection of endangered species or breeds,
including the possible disappearance or long-term damage to
those species or breeds
N
5(d)
(PI)
The disease has a signiﬁcant impact on a long-term effect on
biodiversity or the protection of endangered species or breeds,
including the possible disappearance or long-term damage to
those species or breeds
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufﬁcient evidence or not
relevant to judge.
Table 4: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for avian mycoplasmosis (Mycoplasma gallisepticum,
M. meleagridis) (CI = current impact; PI = potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final outcome
M. gallisepticum M. meleagridis
1 The disease is present in the whole OR part of the Union
territory with an endemic character AND (at the same time)
several Member States or zones of the Union are free of the
disease
N
2.1 The disease is moderately to highly transmissible Y
2.2 There be possibilities of airborne or waterborne or vector-borne
spread
na Y
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low
mortality
Y Y*
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant
consequences on public health, including epidemic potential OR
possible signiﬁcant threats to food safety
N
4 (CI) The disease has a signiﬁcant impact on the economy of the
Union, causing substantial costs, mainly related to its direct
impact on the health and productivity of animals
N
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4 (PI) The disease has a signiﬁcant impact on the economy of the
Union, causing substantial costs, mainly related to its direct
impact on the health and productivity of animals
Y NC
5(a)
(CI)
The disease has a signiﬁcant impact on society, with in
particular an impact on labour markets
N
5(a)
(PI)
The disease has a signiﬁcant impact on society, with in
particular an impact on labour markets
N
5(b)
(CI)
The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
N
5(b)
(PI)
The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
Y NC
5(c)
(CI)
The disease has a signiﬁcant impact on the environment, due
to the direct impact of the disease OR due to the measures
taken to control it
N
5(c)
(PI)
The disease has a signiﬁcant impact on the environment, due
to the direct impact of the disease OR due to the measures
taken to control it
N
5(d)
(CI)
The disease has a signiﬁcant impact on a long-term effect on
biodiversity or the protection of endangered species or breeds,
including the possible disappearance or long-term damage to
those species or breeds
N
5(d)
(PI)
The disease has a signiﬁcant impact on a long-term effect on
biodiversity or the protection of endangered species or breeds,
including the possible disappearance or long-term damage to
those species or breeds
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufﬁcient evidence or not
relevant to judge.
*: Pre-hatch mortality was assessed as production loss.
Table 5: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV (category C
of Article 9) for avian mycoplasmosis (Mycoplasma gallisepticum, M. meleagridis)
(CI = current impact; PI = potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final outcome
M. gallisepticum M. meleagridis
1 The disease is present in the whole OR part of the Union
territory with an endemic character
NC NC
2.1 The disease is moderately to highly transmissible Y
2.2 The disease is transmitted mainly by direct or indirect
transmission
Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has
negligible or no mortality AND often the most observed effect
of the disease is production loss
Y*
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant
consequences on public health, or possible signiﬁcant threats
to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of parts
of the Union, mainly related to its direct impact on certain
types of animal production systems
N
4(PI) The disease has a signiﬁcant impact on the economy of parts
of the Union, mainly related to its direct impact on certain
types of animal production systems
N
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3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 8–11).
The proportion of Y, N or ‘na’ answers are reported, followed by the list of different supporting views
for each answer.
5(a)
(CI)
The disease has a signiﬁcant impact on society, with in
particular an impact on labour markets
N
5(a)
(PI)
The disease has a signiﬁcant impact on society, with in
particular an impact on labour markets
N
5(b)
(CI)
The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
N
5(b)
(PI)
The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
Y NC
5(c)
(CI)
The disease has a signiﬁcant impact on the environment, due
to the direct impact of the disease OR due to the measures
taken to control it
N
5(c)
(PI)
The disease has a signiﬁcant impact on the environment, due
to the direct impact of the disease OR due to the measures
taken to control it
N
5(d)
(CI)
The disease has a signiﬁcant impact on a long-term effect on
biodiversity or the protection of endangered species or breeds,
including the possible disappearance or long-term damage to
those species or breeds
N
5(d)
(PI)
The disease has a signiﬁcant impact on a long-term effect on
biodiversity or the protection of endangered species or breeds,
including the possible disappearance or long-term damage to
those species or breeds
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
*: Pre-hatch mortality was assessed as production loss.
Table 6: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for avian mycoplasmosis (Mycoplasma gallisepticum,
M. meleagridis)
Criteria to be met by the disease: The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated by
measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
Table 7: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV (category E
of Article 9) for avian mycoplasmosis (Mycoplasma gallisepticum, M. meleagridis)
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal
welfare, human health, the economy, society or the environment (If a disease fulﬁls the
criteria as in Article 5, thus being eligible to be listed, consequently category E would
apply)
Y
Colour code: green = consensus (Yes/No).
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Reasoning supporting the judgement
Supporting Yes for 1 (cat.A):
• Sporadic cases of M. gallisepticum are reported.
Supporting Yes for 1 (cat.C):
• The fact sheet reports detections of M. gallisepticum in wild birds, also game birds
(Galliformes), hobby and backyard ﬂocks in multiple MSs where infections do not always lead
to clinical signs. They serve as reservoir. Furthermore, a small number of recent studies have
reported a low seroprevalence in multiple MSs (Latvia, France, Germany, Belgium) with
suggested other MSs with unreported cases.
Reasoning supporting the judgement
Supporting Yes for 1 (cat.A):
• There are only sporadic outbreaks of M. meleagridis. The disease is absent in most of the EU
due to eradication programs.
Supporting Yes for 1 (cat.C):
• M. meleagridis is asymptomatic for wild birds and has been isolated from birds of prey
(Falconiformes) without clinical signs or histopathological alterations in air sac biopsies in
Germany (Lierz et al., 2000). If this Mycoplasma species can be isolated or is detected by
serology in some asymptomatic wild avian species described in the fact sheet these would
serve as a possible, albeit unlikely, route of introduction of the disease for young turkeys
(before sexual maturity) by an airborne transmission. There is no reported surveillance in wild
species throughout the Union.
Table 8: Outcome of the expert judgement related to criterion 1 of Article 9 for M. gallisepticum
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
1(cat.A) The disease is not present in the territory of the Union OR present
only in exceptional cases (irregular introductions) OR present in
only in a very limited part of the territory of the Union
NC 33 67 0
1(cat.C) The disease is present in the whole OR part of the Union territory
with an endemic character
NC 56 44 0
NC: non-consensus; number of judges: 9.
Table 9: Outcome of the expert judgement related to criterion 1 of Article 9 for M. meleagridis
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
1(cat.A) The disease is not present in the territory of the Union OR present
only in exceptional cases (irregular introductions) OR present in
only in a very limited part of the territory of the Union
NC 33 67 0
1(cat.C) The disease is present in the whole OR part of the Union territory
with an endemic character
NC 67 33 0
NC: non-consensus; number of judges: 9.
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Reasoning supporting the judgement
Supporting Yes for 4 (cat.A,B):
• Both Mycoplasma species resulted in signiﬁcant problems before implementation of control
programmes and could thus do so again. M. meleagridis primarily affects turkey breeders.
Supporting No for 4 (cat.A,B):
• 5–6% decrease in egg hatchability in turkeys is not considered signiﬁcant.
• The current position will potentially not change. M. meleagridis may be a concern primarily in
turkey breeders where high biosecurity practices operate, thus there is low potential to change.
Reasoning supporting the judgement
Supporting Yes:
• Both pathogens resulted in signiﬁcant problems before implementation of control programmes
and could thus do so again. M. meleagridis primarily affects turkey breeders.
• There would be high mortality and morbidity, if no control was in place.
• The infection can cause clinical signs with pain, and with a potentially high prevalence, thus
the impact on animal welfare can be signiﬁcant. There would not only be decreased egg
hatchability, but also 10–25% sacculitis and skeleton deformations.
Supporting No:
• M. meleagridis may be a concern primarily in turkey breeders where high biosecurity practices
operate, thus, there is low potential to change.
• The main symptom is embryo mortality for M. meleagridis, and that would not be on a large
number of animals, but only in breeders.
3.3.2. Outcome of the assessment of criteria in Annex IV for avian
mycoplasmosis (Mycoplasma gallisepticum, M. meleagridis) for the
purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 3–7. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
With respect to different type of impact where the assessment is divided into current and potential
impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’ and, in case of
no ‘Y’, the assessment is inconclusive if at least one outcome is ‘NC’.
Table 11: Outcome of the expert judgement related to criterion 5(b)(PI) of Article 9 for
M. meleagridis
Question
Final
outcome
Response
Y (%) N (%) na (%)
5(b) The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
NC 60 40 0
NC: non-consensus; number of judges: 10.
Table 10: Outcome of the expert judgement related to criterion 4(PI) of Article 9 for M. meleagridis
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
4(cat.A,
B)
The disease has a signiﬁcant impact on the economy of the Union,
causing substantial costs, mainly related to its direct impact on the
health and productivity of animals
NC 40 60 0
NC: non-consensus; number of judges: 10.
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A description of the outcome of the assessment of criteria in Annex IV for avian mycoplasmosis
(M. gallisepticum, M. meleagridis) for the purpose of categorisation as in Article 9 of the AHL is
presented in Tables 12 and 13.
Table 13: Outcome of the assessment of criteria in Annex IV for M. meleagridis for the purpose of
categorisation as in Article 9 of the AHL (CI = current impact; PI = potential impact)
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
G
eo
g
rap
h
ical
d
istrib
u
tio
n
T
ran
sm
issib
ility
R
o
u
tes
o
f
tran
sm
issio
n
M
u
ltip
le
sp
ecies
M
o
rb
id
ity
an
d
m
o
rtality
Z
o
o
n
o
tic
p
o
ten
tial
Im
p
act
o
n
eco
n
o
m
y
Im
p
act
o
n
so
ciety
Im
p
act
o
n
an
im
al
w
elfare
Im
p
act
o
n
en
viro
n
m
en
t
Im
p
act
o
n
b
io
d
iversity
A NC N Y Y N N CI: N
PI: NC
N CI: N
PI: NC
N N
B N Y Y Y Y N CI: N
PI: NC
N CI: N
PI: NC
N N
C NC Y Y Y Y N N N CI: N
PI: NC
N N
D Y
E Y
Table 12: Outcome of the assessment of criteria in Annex IV for M. gallisepticum for the purpose
of categorisation as in Article 9 of the AHL (CI = current impact; PI = potential impact)
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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A NC N na Y N N CI: N
PI: Y
N CI: N
PI: Y
N N
B N Y na Y Y N CI: N
PI: Y
N CI: N
PI: Y
N N
C NC Y Y Y Y N N N CI: N
PI: Y
N N
D Y
E Y
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According to the assessment here performed, avian mycoplasmosis (M. gallisepticum,
M. meleagridis) complies with the following criteria of the Sections 1–5 of Annex IV of the AHL for the
application of the disease prevention and control rules referred to in points (a)–(e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment M. gallisepticum complies with criterion 2.3,
but not with 2.1 and 2.4. The assessment is not applicable on criterion 2.2 and inconclusive
on compliance with criterion 1. M. meleagridis complies with criteria 2.2 and 2.3, but not
with 2.1 and 2.4 and the assessment is inconclusive on compliance with criterion 1. To be
eligible for category A, a disease needs to comply additionally with one of the criteria of the
second set (3, 4, 5a–d) and M. gallisepticum complies with criteria 4 and 5b, but not with 3,
5a, 5c and 5d. M. meleagridis does not comply with criteria 3, 5a, 5c and 5d and the
assessment is inconclusive on compliance with criteria 4 and 5b.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment M. gallisepticum complies with criteria 2.1, 2.3
and 2.4, but not with 1 and the assessment is not applicable on criterion 2.2. M. meleagridis
complies with criteria 2.1, 2.2, 2.3 and 2.4, but not with 1. To be eligible for category B, a
disease needs to comply additionally with one of the criteria of the second set (3, 4, 5a–d)
and M. gallisepticum complies with criteria 4 and 5b, but not with 3, 5a, 5c and 5d.
M. meleagridis does not comply with criteria 3, 5a, 5c and 5d and the assessment is
inconclusive on compliance with criteria 4 and 5b.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment M. gallisepticum and M. meleagridis comply
with criteria 2.1, 2.2, 2.3 and 2.4 and the assessment is inconclusive on compliance with
criterion 1. To be eligible for category C, a disease needs to comply additionally with one of
the criteria of the second set (3, 4, 5a–d) and M. gallisepticum complies only with criterion
5b. M. meleagridis does not comply with any of the criteria and the assessment is
inconclusive on compliance with criterion 5b.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or 5
of Annex IV of the AHL and with the speciﬁc criterion D of Section 4, with which avian
mycoplasmosis (M. gallisepticum, M. meleagridis) complies.
5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5, with which avian
mycoplasmosis (M. gallisepticum, M. meleagridis) complies.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
avian mycoplasmosis (M. gallisepticum, M. meleagridis). The Article 8(3) criteria are about animal
species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that
such role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.4 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for avian mycoplasmosis
4 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors, the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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(M. gallisepticum, M. meleagridis) according to the criteria of Article 8(3) of the AHL are as displayed
in Tables 14 and 15.
4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, avian mycoplasmosis (M. gallisepticum,
M. meleagridis) complies with all criteria of the ﬁrst set and with one criterion of the second
set and therefore can be considered eligible to be listed for Union intervention as laid down in
Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, avian mycoplasmosis (M. gallisepticum,
M. meleagridis) meets the criteria as in Sections 4 and 5 of Annex IV of the AHL, for the
application of the disease prevention and control rules referred to in points (d) and (e) of Article 9
(1) of the AHL, while it is inconclusive whether avian mycoplasmosis (Mycoplasma gallisepticum,
M. meleagridis) complies with the criteria as in Section 3 of Annex IV of the AHL, for the
application of the disease prevention and control rules referred to in point (c) of Article 9(1) of the
Table 14: Main animal species to be listed for Mycoplasma gallisepticum according to criteria of
Article 8 (source: data reported in Section 3.1.1.1)
Order Family Genus/Species
Susceptible and
reservoir
Galliformes Phasianidae Gallus spp., Meleagris spp., pheasants (Phasianinae),
Perdix perdix, Alectoris chukar, Coturnix japonica
Odontophoridae Colinus virginianus
Columbiformes Columbidae Columba palumbus
Pelecaniformes Ardeidae Ardea cinerea
Anseriformes Anatidae Not speciﬁed
Passeriformes Corvidae Pica pica
Fringillidae Haemorhous mexicanus, Spinus tristis, Pinicola
enucleator, Coccothraustes vespertinus, Haemorhous
purpureus, Serinus canaria domestica
Corvidae Corvus frugilegusCyanocitta cristata
Passeridae Not speciﬁed
Psittaciformes Not speciﬁed Not speciﬁed
Vectors None
Table 15: Main animal species to be listed for Mycoplasma meleagridis according to criteria of
Article 8 (source: data reported in Section 3.1.1.1)
Order Family Genus/Species
Susceptible Galliformes Phasianidae Meleagris spp.
pheasants (Phasianinae)
Tympanuchus pallidicinctus
Coturnix japonica
Gallus gallus
Odontophoridae Callipepla squamata
Columbiformes Columbidae Not speciﬁed
Falconiformes Not speciﬁed Not speciﬁed
Reservoir None
Vectors None
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AHL. Compliance of avian mycoplasmosis with the criteria as in Section 3 is dependent on a
decision on criteria 1 and 5b.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list
of animal species that should be considered candidates for listing in accordance with Article 8 of the
AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for avian mycoplasmosis (M. gallisepticum, M. meleagridis) according to Article 8(3) of
the AHL are mainly domestic and wild bird species belonging to the orders of Galliformes,
Columbiformes, Pelecaniformes, Anseriformes, Passeriformes, and Psittaciformes for
M. gallisepticum; and Galliformes, Columbiformes and Falconiformes for M. meleagridis, as
reported in Tables 14 and 15 in Section 3.4 of the present document.
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